| Vol. 9.08 – 2 March, 2021 |
| |
|
|
| Researchers produced affinity-matured class II dimers that stain antigen-specific T cells better than conventional multimers in both in vitro and ex vivo analyses. [Nature Biotechnology] |
|
|
|
| PUBLICATIONSRanked by the impact factor of the journal |
|
|
|
| In patient-derived melanoma cells and autologous tumor-infiltrating lymphocyte co-cultures, scientists profiled transcriptomes and 20 proteins in ~218,000 cells under ~750 perturbations associated with cancer cell-intrinsic immune checkpoint inhibitor resistance. [Nature Genetics] |
|
|
|
| Investigators showed that PDAC tumor cells present an increased sialylation that could be recognized by Siglec-7 and Siglec-9 on myeloid cells. [Nature Communications] |
|
|
|
| The authors report their discovery of B-cell lymphoma extra-large as a potential molecular target of tumor-infiltrating Tregs. [Nature Communications] |
|
|
|
| Scientists developed CRISPR-edited universal off-the-shelf CD19/CD22 dual-targeted CAR-T cells as a novel therapy for relapsed/refractory acute lymphoblastic leukemia. [Clinical Cancer Research] |
|
|
|
| Researchers demonstrated that CD20 controlled the nanoscale organization of receptors on the surface of resting B lymphocytes. [Proceedings of the National Academy of Sciences of the United States of America] |
|
|
|
| Investigators undertook experiments to define structural determinants of hypoxia-inducible factor that potentiate antitumor efficacy in cytotoxic T cells. [Cancer Immunology Research] |
|
|
|
| Scientists modulated interferon regulatory factor 4 (IRF4) levels by transfecting chronic lymphocytic leukemia cells with an IRF4 vector or by silencing using small-interfering RNAs. [Leukemia] |
|
|
|
| The authors identified differentially expressed miRNAs in the peripheral blood of anti-citrullinated protein antibodies (ACPA)-positive individuals with arthralgia at risk of rheumatoid arthritis compared to healthy controls. [Scientific Reports] |
|
|
|
| Researchers generated human macrophages in the presence of either macrophage-colony stimulating factor or granulocyte–macrophage-colony stimulating factor to obtain M-MØ and GM-MØ. [Scientific Reports] |
|
|
|
|
| Scientists summarize recent studies investigating the involvement of TAMs in immune checkpoint inhibition, tumor vaccines and adoptive cell transfer therapies. [Signal Transduction and Targeted Therapy] |
|
|
|
| The authors summarize the recent discoveries that have deepened our understanding of the exhaustion program of cytotoxic CD8+ T cells. [Experimental and Molecular Medicine] |
|
|
|
|
| MaxiVAX SA and Minaris Regenerative Medicine GmbH have entered into a manufacturing agreement for MVX-ONCO-2, a cell-based immunotherapy for the treatment of cancers such as chordoma, head and neck, and other solid tumors. [MaxiVAX SA] |
|
|
|
|
| March 23 – 25, 2021 Virtual |
|
|
|
|
|
| Houston Methodist Research Institute – Houston, Texas, United States |
|
|
|
| University of Notre Dame – Notre Dame, Indiana, United States |
|
|
|
| Oklahoma Medical Research Foundation – Oklahoma City, Oklahoma, United States |
|
|
|
| The University of Texas Southwestern Medical Center – Dallas, Texas, United States |
|
|
|
| Oklahoma Medical Research Foundation – Oklahoma City, Oklahoma, United States |
|
|
|
|